These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 24259608)
1. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer. Perkins SL; Cole SW Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608 [TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Mitchell EP Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896 [TBL] [Abstract][Full Text] [Related]
3. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Chung C; Pherwani N Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964 [TBL] [Abstract][Full Text] [Related]
4. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147 [TBL] [Abstract][Full Text] [Related]
5. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191 [TBL] [Abstract][Full Text] [Related]
6. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509 [TBL] [Abstract][Full Text] [Related]
7. Aflibercept: A Review in Metastatic Colorectal Cancer. Syed YY; McKeage K Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913 [TBL] [Abstract][Full Text] [Related]
8. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268 [TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187 [TBL] [Abstract][Full Text] [Related]
10. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]. André T; Chibaudel B Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539 [TBL] [Abstract][Full Text] [Related]
11. Ziv-aflibercept (Zaltrap) for metastatic colorectal cancer. Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836346 [No Abstract] [Full Text] [Related]
12. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237 [TBL] [Abstract][Full Text] [Related]
13. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885 [TBL] [Abstract][Full Text] [Related]
14. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335 [TBL] [Abstract][Full Text] [Related]
16. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738 [TBL] [Abstract][Full Text] [Related]
17. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab. Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116 [TBL] [Abstract][Full Text] [Related]
18. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Joulain F; Proskorovsky I; Allegra C; Tabernero J; Hoyle M; Iqbal SU; Van Cutsem E Br J Cancer; 2013 Oct; 109(7):1735-43. PubMed ID: 24045663 [TBL] [Abstract][Full Text] [Related]
19. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. Chau I; Joulain F; Iqbal SU; Bridgewater J BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418 [TBL] [Abstract][Full Text] [Related]
20. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]